Johnson & Johnson pays $50M to resolve its ugly divorce with Emergent BioSolutions

2024-07-09

Preview

来源: FiercePharma

Emergent BioSolutions will receive $50 million from Johnson & Johnson to resolve a contract dispute over production of COVID-19 vaccines COVID-19 vaccines.

Johnson & Johnson will pay Emergent BioSolutions $50 million to settle a two-year contract squabble and bring closure to an ill-fated, government-arranged partnership between the biopharma giant and the contract manufacturer to produce COVID-19 vaccines COVID-19 vaccines.

According to a filing with the Securities and Exchange Commission (SEC), J&J has agreed to pay Emergent $50 million by the end of this month to resolve the CDMO’s claims of breach of contract.

In 2022, J&J terminated a five-year deal that called for Emergent to produce drug substance for J&J’s COVID-19 vaccine COVID-19 vaccine. The Maryland manufacturer responded in an SEC filing that J&J was on the hook for $420 million for bailing on the agreement. Two months later, J&J filed its own breach of contract complaint against Emergent and asked for an arbitration.

The contract battle began after Emergent made high-profile errors at its sprawling Bayside plant in Baltimore where it was producing COVID vaccines for AstraZeneca and J&J. The mistakes caused millions of contaminated vaccine doses to be discarded and led the FDA to hand control of the plant over to J&J in April 2021.

Meanwhile, J&J was struggling with rare blood clotting issues with its COVID vaccine, which led the FDA to limit its use in May 2022.

In response to the settlement agreement Monday, Emergent’s share price rose by 2%. Since the start of the year, its shares are up 214% as the company has shown signs of recovering from its COVID debacle.

In May, new CEO Joe Papa announced a restructuring that includes the closure of two of its plants in Maryland, including the Baltimore Bayside facility, and a staff reduction by 300 roles.

Three weeks ago, the company also announced the sale of its smaller, fill-finish Camden facility in Baltimore to Bora Pharmaceuticals for $30 million.

Last week, Emergent revealed that it had signed a U.S. government contract for more than $250 million to produce vaccines to be stockpiled for use against anthrax, botulism and smallpox. The company will produce the shots from its sites in Winnipeg, Canada, and Lansing, Michigan.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构